StudyFinder
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
RECRUITING
18 years to 80 years old
Inclusion Criteria:
* The participant is within the ages of 18 and 80 years old
* The participant had a kidney transplant (living or deceased donor) at least 6 months before the study
* The participant has received a diagnosis of active or chronic active antibody-mediated rejection (AMR) with detectable donor-specific antibodies at time of the study
* A participant may be allowed into the study if they receive the following medications:
• Received mycophenolate mofetil for at least 20 weeks before the study
• Has remained on a stable dose of mycophenolate mofetil and tacrolimus for at least 4 weeks before being allowed to participate in the study
• Has remained on tacrolimus doses between 5 to 10 ng/mL at least 4 weeks before being allowed to participate in the study
• Steroid dose was between 0 to 10 mg per day of prednisone (or dose equivalent) for at least 4 weeks before being allowed to participate in the study
Exclusion Criteria:
* Confirmed T-cell or mixed rejection at time of the study
* Recent change in immunosuppressive therapy agents
* Any other medical condition that, in the investigator's opinion, would interfere with the results of the study or put the participant at undue risk
* Pregnant or lactating state or intention to become pregnant during the study
The complete list of criteria can be found in the protocolCOMBINATION_PRODUCT: Efgartigimod PH20 SC - prefilled syringe, OTHER: Placebo PH20 SC - prefilled syringe
Antibody-mediated Rejection
Active AMR, Chronic active AMR, Late AMR
Sabine Coppieters, MD - clinicaltrials@argenx.com
PHASE2
NCT06503731